Rapid Diagnostics Market-By Product (Infectious Disease Testing, Glucose Monitoring, Cardiometabolic Testing, Coagulation Testing Products, Pregnancy & Fertility Testing, & Others), Distribution Channel, End-use & Forecast, 2023-2032

Description

List of Tables

Global Rapid Diagnostics Market will witness significant growth between 2023 and 2032. The growing demand for quick and accurate medical insights drives demand for rapid diagnostic tests. Timely results aid in prompt decision-making, critical for managing and personalized treatments of infectious diseases. Technological advancements in biosensors, point-of-care devices, and molecular diagnostics enhance test accuracy and accessibility. For instance, in May 2023, The U.S. Food and Drug Administration (FDA) granted 510(k) approval to Nano-X Imaging Ltd., a pioneer in medical imaging technology, allowing it to commercialize the multi-source Nanox.ARC and its supporting cloud-based infrastructure.

Rising global health concerns, such as pandemics, underscore the need for efficient disease detection. Furthermore, streamlined regulatory pathways and increased funding will expedite market growth. As healthcare systems prioritize speed, accuracy, and patient-centric care, the rapid diagnostics market continues to evolve, catering to diagnostic demands and transforming medical practices.

The overall Rapid Diagnostics Market is classified based on product, distribution channel, end-use, and region.

Based on the product, the cardiometabolic testing segment size will bolster considerably from 2023 to 2032. As cardiovascular diseases and metabolic disorders rise, efficient and timely diagnostics are crucial. Rapid tests enable swift risk assessment, aiding in early intervention and personalized treatment strategies. Point-of-care devices and biomarker advancements provide quick insights into heart health and metabolic status. With health systems emphasizing preventive care and patients seeking immediate results, the demand for rapid cardiometabolic testing is growing, enhancing disease management and overall wellness.

By distribution channel, the E-commerce segment will capture a noteworthy rapid diagnostics market share by 2032. As online shopping becomes increasingly prevalent, rapid tests offer an efficient solution for ensuring safe and seamless transactions. E-commerce companies are adopting rapid diagnostics to screen employees for infectious diseases and maintain operational continuity. Swift testing safeguards both employees and customers, enhancing confidence in online shopping platforms. As health and convenience become intertwined, the integration of rapid diagnostics into E-commerce is meeting the evolving needs of the digital marketplace.

Regarding the end-user, the rapid diagnostics industry from the hospital pharmacies segment will witness appreciable growth over 2023-2032. These diagnostics offer quick and accurate results, enabling pharmacy staff to make informed decisions about patient treatments and medications. Rapid tests aid in detecting infectious diseases, ensuring timely isolation and treatment protocols. With efficient point-of-care testing, hospital pharmacies enhance patient care, reduce waiting times, and contribute to infection control. As healthcare facilities prioritize prompt and accurate diagnostics, the adoption of rapid tests in hospital pharmacies is on the rise, reshaping patient management and healthcare delivery.

Regionally, the Europe rapid diagnostics industry will gain traction during 2023-2032 due to the region's focus on efficient healthcare delivery. The prevalence of infectious diseases and the need for prompt screening drive adoption. Additionally, industries like food safety and environmental monitoring benefit from rapid diagnostics. As European countries emphasize health preparedness and swift decision-making, the market for rapid diagnostics continues to grow, fostering improved public health outcomes and operational efficiency.

Product Code: 5745

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Rapid diagnostics industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product trends
- 2.1.4 Purchase trends
- 2.1.5 Technology/platform trends
- 2.1.6 Distributional Channel trends
- 2.1.7 End-use trends

Chapter 3 Rapid Diagnostics Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of infectious disease
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Increasing popularity of rapid diagnostic tests
  - 3.2.1.4 Rising awareness regarding early diagnosis among People
  - 3.2.1.5 Increasing government initiatives for the diagnosis of infectious diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Low accuracy of results
  - 3.2.2.2 Availability of substitute product
  - 3.2.2.3 Stringent regulatory framework
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By purchase
- 3.3.3 By technology/platform
- 3.3.4 By distribution channel
- 3.3.5 By end-use
3.4 COVID-19 impact analysis
3.5 Technology landscape
3.6 Future market trends
3.7 Gap analysis
3.8 Regulatory landscape
- 3.8.1 U.S.
- 3.8.2 Europe
3.9 Reimbursement scenario
3.10 Porter's analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2021

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard, 2022

Chapter 5 Rapid Diagnostics Market Size and Forecast, By Product (USD Million)

5.1 Key product trends
- 5.1.1 Infectious Disease Testing
  - 5.1.1.1 Respiratory Infection Testing Products
  - 5.1.1.2 Influenza
  - 5.1.1.3 Hepatitis
  - 5.1.1.4 HIV
  - 5.1.1.5 Others
- 5.1.2 Glucose Monitoring
- 5.1.3 Cardiometabolic Testing
- 5.1.4 Coagulation testing products
- 5.1.5 Pregnancy and Fertility Testing
- 5.1.6 Tumor/Cancer marker testing products
- 5.1.7 Urinalysis testing products
- 5.1.8 Cholesterol testing products
- 5.1.9 Hematology testing products
- 5.1.10 Drug-of-Abuse (DoA) testing products
- 5.1.11 Fecal occult testing products

Chapter 6 Rapid Diagnostics Market Size and Forecast, By Purchase (USD Million)

6.1 Key purchase trends
- 6.1.1 OTC
- 6.1.2 Prsecription

Chapter 7 Rapid Diagnostics Market Size and Forecast, By Technology/Platform (USD Million)

7.1 Key technology/platform trends
- 7.1.1 Flow-Through
- 7.1.2 Solid Phase
- 7.1.3 Lateral Flow
- 7.1.4 Agglutination Assays
- 7.1.5 Others

Chapter 8 Rapid Diagnostics Market Size and Forecast Market, By Distribution Channel (USD Million)

8.1 Key distribution channel trends
- 8.1.1 Hospital Pharmacies
- 8.1.2 Brick & Mortar
- 8.1.3 E-commerce
- 8.1.4 Others

Chapter 9 Rapid Diagnostics Market Size and Forecast Market, By End-use (USD Million)

9.1 Key end-use trends
- 9.1.1 Diagnostic Centers
- 9.1.2 Homecare Settings
- 9.1.3 Hospital Pharmacies
- 9.1.4 Others

Chapter 10 Rapid Diagnostics Market Size and Forecast Market , By Region (USD Million)

10.1 Key regional trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Poland
- 10.3.7 Switzerland
- 10.3.8 The Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Indonesia
- 10.4.7 Thailand
- 10.4.8 Philippines
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Columbia
- 10.5.5 Chile
- 10.5.6 Peru
10.6 Middle East & Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Egypt
- 10.6.5 Iran
- 10.6.6 Israel

Chapter 11 Company Profiles

11.1 Abbott
11.2 Roche
11.3 Danaher Corporation (HemoCue & Radiometer)
11.4 Quidel Corporation
11.5 Bio-Rad Laboratories
11.6 ACON Laboratories Inc.
11.7 Alfa Scientific Designs Inc.
11.8 Artron Laboratories Inc.
11.9 BioMerieux
11.10 Becton, Dickinson and Company
11.11 Qiagen N.V
11.12 Hologic